[ad_1]
NEW YORK, Oct. 26, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) and certain of its officers. The class action, filed in the United States District Court for the Central District of Californiaand docketed under 22-cv-06764, is on behalf of a class of all persons and entities who purchased the publicly traded securities of Fulgent securities between March 22, 2019 and August 4, 2022both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you…
Full story available on Benzinga.com
[ad_2]
Source link
